Real-world data in patients with hepatocellular carcinoma treated with transarterial chemoembolization: the second interim analysis of OPTIMIS

Markus Peck‐Radosavljevic; Masatoshi Kudo; H.C. Lee; Ann‐Lii Cheng; Keiko Nakajima; Jean‐Luc Raoul

doi:10.1016/s0168-8278(18)30614-7

Back

Real-world data in patients with hepatocellular carcinoma treated with transarterial chemoembolization: the second interim analysis of OPTIMIS

Article 2018 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2018

Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis.

Markus Peck‐Radosavljevic, Masatoshi Kudo, Jean‐Luc Raoul, Han Chu Lee, Thomas Decaens, Jeong Heo, Shi‐Ming Lin, Hong Shan, Yefa Yang, Inga Bayh, Keiko Nakajima, Ann‐Lii Cheng

Article2014

An International Observational Study to Assess the Use of Sorafenib After Transarterial Chemoembolization (Tace) in Patients with Hepatocellular Carcinoma (Hcc): Optimis

Jean‐Luc Raoul, Markus Peck‐Radosavljevic, H.C. Lee, Masatoshi Kudo, Keiko Nakajima, Ann‐Lii Cheng

Article2014

OPTIMIS: An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).

Markus Peck‐Radosavljevic, Jean‐Luc Raoul, Han Chu Lee, Masatoshi Kudo, Keiko Nakajima, Ann‐Lii Cheng

Article2015

P1338 : An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): optimis

Markus Peck‐Radosavljevic, Jean‐Luc Raoul, H.C. Lee, Masatoshi Kudo, Keiko Nakajima, Ann‐Lii Cheng

Article2019

Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization

Masatoshi Kudo